# TRIAP1

## Overview
TRIAP1, or TP53-regulated inhibitor of apoptosis 1, is a gene that encodes a protein involved in the regulation of apoptosis and mitochondrial function. The TRIAP1 protein is characterized by its role in the mitochondrial intermembrane space, where it forms complexes with PRELI proteins to facilitate the transport of phosphatidic acid, a precursor for cardiolipin synthesis. This process is crucial for maintaining mitochondrial membrane integrity and function, thereby preventing apoptosis in healthy cells (Miliara2016Structural; Potting2013TRIAP1PRELI). The protein is regulated by the tumor suppressor p53 and is implicated in cell-cycle progression and stress response (Potting2013TRIAP1PRELI). TRIAP1's interactions with other proteins, such as Hsp70, further underscore its role in inhibiting apoptosome formation and caspase activation, contributing to its anti-apoptotic function (Li2021Abnormal). The gene's expression and the protein's activity are of particular interest in cancer research, where TRIAP1 is often overexpressed, leading to enhanced tumor cell survival and drug resistance (Nedara2022Relevance; ADAMS2015Apoptosis).

## Structure
The TRIAP1 protein, also known as Mdm35 in yeast, is characterized by a twin Cx9C motif, which is essential for its transfer from the cytosol to the mitochondrial intermembrane space via the mitochondrial assembly 40 (Mia40) disulfide relay system (Miliara2016Structural). The protein has a highly conserved structure with an antiparallel α-hairpin stabilized by disulfide bonds, forming a suitable substrate for the Tim40/MIA import system (Miliara2016Structural). The crystal structures of human TRIAP1 reveal a conserved hydrophobic surface that may serve as a folding template for PRELI domain recruitment (Miliara2016Structural).

In terms of quaternary structure, TRIAP1 forms complexes with PRELI proteins, such as PRELID1 and PRELID3b, which are involved in lipid transport across mitochondrial membranes (Miliara2019Structural). These complexes have been structurally characterized, showing a conserved architecture of three α-helices and a seven-stranded antiparallel β-sheet (Miliara2016Structural). The TRIAP1-SLMO1 and Mdm35-Ups1 complexes exhibit similar conformations, with the TRIAP1-SLMO1 interface involving close contacts between conserved hydrophobic regions, suggesting a role in phospholipid binding and release (Miliara2016Structural). TRIAP1 is also noted for its role in mitochondrial import and folding of the PRELI domain, as well as modulating its membrane affinity (Miliara2019Structural).

## Function
TRIAP1, also known as TP53-regulated inhibitor of apoptosis 1, is a protein that plays a crucial role in preventing apoptosis in healthy human cells. It is involved in the intramitochondrial transport of phosphatidic acid, a precursor for cardiolipin synthesis, which is essential for maintaining mitochondrial membrane integrity and function (Potting2013TRIAP1PRELI). TRIAP1 forms a complex with the PRELI protein in the mitochondrial intermembrane space, facilitating the accumulation of cardiolipin, which is necessary for the stability of respiratory supercomplexes and apoptotic resistance (Potting2013TRIAP1PRELI).

TRIAP1 also interacts with Hsp70-binding protein 1 to prevent the formation of the apoptosome and inhibit caspase activation, thereby modulating apoptotic pathways and promoting cell survival (Li2021Abnormal). This protein is regulated by p53 and is involved in cell-cycle progression, with its expression being upregulated under certain stress conditions (Potting2013TRIAP1PRELI). TRIAP1's role in lipid transfer and mitochondrial integrity is evolutionarily conserved, highlighting its fundamental importance in cellular physiology (Potting2013TRIAP1PRELI). Its activity is crucial for maintaining mitochondrial morphology and function, influencing cellular lipid and metabolic profiles, and supporting cell proliferation and survival (Nedara2022Relevance).

## Clinical Significance
Alterations in the expression of the TRIAP1 gene have significant clinical implications, particularly in cancer. TRIAP1 is overexpressed in various cancers, including colorectal cancer, nasopharyngeal carcinoma, breast cancer, and ovarian cancer, where it is associated with poor prognosis and drug resistance (Zhang2019TRIAP1; Li2016Overexpression; Nedara2022Relevance; ADAMS2015Apoptosis). In colorectal cancer, high TRIAP1 levels support tumor growth and proliferation by inhibiting apoptosis and promoting cell cycle progression (Nedara2022Relevance). In nasopharyngeal carcinoma, TRIAP1 overexpression is linked to enhanced cell proliferation and reduced apoptosis, contributing to tumor progression and poor clinical outcomes (Li2016Overexpression).

TRIAP1 also plays a role in drug resistance. In breast cancer, its upregulation is associated with resistance to doxorubicin, a common chemotherapy drug, by inhibiting apoptosis (ADAMS2015Apoptosis). Similarly, in ovarian cancer, TRIAP1 inhibition increases sensitivity to cisplatin, suggesting its potential as a therapeutic target to overcome drug resistance (Zhang2019TRIAP1). These findings highlight TRIAP1's role in cancer cell survival and its potential as a target for therapeutic interventions.

## Interactions
TRIAP1, also known as TP53 regulated inhibitor of apoptosis 1, is involved in several protein interactions that are crucial for its role in apoptosis regulation and mitochondrial function. TRIAP1 forms a complex with PRELI proteins, such as PRELI1 and PRELI2, in the mitochondrial intermembrane space. This complex is essential for the intramitochondrial transport of phosphatidic acid, which is critical for cardiolipin synthesis, a key component of mitochondrial membranes (Potting2013TRIAP1PRELI; Schlattner2014Mitochondrial). The interaction between TRIAP1 and PRELI protects PRELI from proteolysis by the i-AAA protease YME1L, indicating a stabilizing role for TRIAP1 in this complex (Potting2013TRIAP1PRELI).

TRIAP1 also interacts with HSP70 in the cytoplasm, where it inhibits the formation of the apoptosome and the activation of caspase-9, thereby preventing apoptosis. This interaction is particularly significant in the context of cancer, where TRIAP1 contributes to drug resistance by helping cancer cells evade apoptosis (ADAMS2015Apoptosis). Additionally, TRIAP1 is involved in maintaining redox homeostasis in non-small cell lung cancer by regulating various antioxidant proteins, although the exact mechanisms of these interactions remain unclear (Hao2020TRIAP1).


## References


[1. (Hao2020TRIAP1) Chun‐cheng Hao, Jia‐ning Luo, Cui‐yang Xu, Xin‐yu Zhao, Zhen‐bin Zhong, Xiao‐nan Hu, Xiao‐ming Jin, and Xiaofeng Ge. Triap1 knockdown sensitizes non‐small cell lung cancer to ionizing radiation by disrupting redox homeostasis. Thoracic Cancer, 11(4):1015–1025, February 2020. URL: http://dx.doi.org/10.1111/1759-7714.13358, doi:10.1111/1759-7714.13358. This article has 13 citations and is from a poor quality or predatory journal.](https://doi.org/10.1111/1759-7714.13358)

[2. (Li2016Overexpression) Yingqin Li, Xinran Tang, Qingmei He, Xiaojing Yang, Xianyue Ren, Xin Wen, Jian Zhang, Yaqin Wang, Na Liu, and Jun Ma. Overexpression of mitochondria mediator gene triap1 by mir-320b loss is associated with progression in nasopharyngeal carcinoma. PLOS Genetics, 12(7):e1006183, July 2016. URL: http://dx.doi.org/10.1371/journal.pgen.1006183, doi:10.1371/journal.pgen.1006183. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1006183)

[3. (Nedara2022Relevance) Kenza Nedara, Camille Reinhardt, Emilie Lebraud, Giuseppe Arena, Céline Gracia, Valérie Buard, Catherine Pioche-Durieu, Florence Castelli, Benoit Colsch, Paule Bénit, Pierre Rustin, Benoit Albaud, Pierre Gestraud, Sylvain Baulande, Nicolas Servant, Eric Deutsch, Jean-Marc Verbavatz, Catherine Brenner, Fabien Milliat, and Nazanine Modjtahedi. Relevance of the triap1/p53 axis in colon cancer cell proliferation and adaptation to glutamine deprivation. Frontiers in Oncology, October 2022. URL: http://dx.doi.org/10.3389/fonc.2022.958155, doi:10.3389/fonc.2022.958155. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.958155)

[4. (Miliara2019Structural) Xeni Miliara, Takashi Tatsuta, Jamie-Lee Berry, Sarah L. Rouse, Kübra Solak, Dror S. Chorev, Di Wu, Carol V. Robinson, Stephen Matthews, and Thomas Langer. Structural determinants of lipid specificity within ups/preli lipid transfer proteins. Nature Communications, March 2019. URL: http://dx.doi.org/10.1038/s41467-019-09089-x, doi:10.1038/s41467-019-09089-x. This article has 46 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-09089-x)

[5. (Miliara2016Structural) Xeni Miliara and Stephen Matthews. Structural comparison of yeast and human intra-mitochondrial lipid transport systems. Biochemical Society Transactions, 44(2):479–485, April 2016. URL: http://dx.doi.org/10.1042/bst20150264, doi:10.1042/bst20150264. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20150264)

[6. (Potting2013TRIAP1PRELI) Christoph Potting, Takashi Tatsuta, Tim König, Mathias Haag, Timothy Wai, Mari J. Aaltonen, and Thomas Langer. Triap1/preli complexes prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid. Cell Metabolism, 18(2):287–295, August 2013. URL: http://dx.doi.org/10.1016/j.cmet.2013.07.008, doi:10.1016/j.cmet.2013.07.008. This article has 170 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cmet.2013.07.008)

[7. (ADAMS2015Apoptosis) CAROLINE ADAMS, GIULIA CAZZANELLI, SABEENA RASUL, BEN HITCHINSON, YUNHUI HU, R CHARLES COOMBES, SELINA RAGUZ, and ERNESTO YAGÜE. Apoptosis inhibitor triap1 is a novel effector of drug resistance. Oncology Reports, 34(1):415–422, May 2015. URL: http://dx.doi.org/10.3892/or.2015.3988, doi:10.3892/or.2015.3988. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2015.3988)

[8. (Li2021Abnormal) Linxia Li, Kaihan Yang, Fang Ye, Yi Xu, Lili Cao, and Jia Sheng. Abnormal expression of triap1 and its role in gestational diabetes mellitus‑related pancreatic β cells. Experimental and Therapeutic Medicine, January 2021. URL: http://dx.doi.org/10.3892/etm.2021.9618, doi:10.3892/etm.2021.9618. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2021.9618)

[9. (Zhang2019TRIAP1) Tian-Mei Zhang. Triap1 inhibition activates the cytochrome &lt;b&gt;&lt;i&gt;c&lt;/i&gt;&lt;/b&gt;/apaf-1/caspase-9 signaling pathway to enhance human ovarian cancer sensitivity to cisplatin. Chemotherapy, 64(3):119–128, 2019. URL: http://dx.doi.org/10.1159/000501633, doi:10.1159/000501633. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000501633)

[10. (Schlattner2014Mitochondrial) Uwe Schlattner, Malgorzata Tokarska-Schlattner, Denis Rousseau, Mathieu Boissan, Carmen Mannella, Richard Epand, and Marie-Lise Lacombe. Mitochondrial cardiolipin/phospholipid trafficking: the role of membrane contact site complexes and lipid transfer proteins. Chemistry and Physics of Lipids, 179:32–41, April 2014. URL: http://dx.doi.org/10.1016/j.chemphyslip.2013.12.008, doi:10.1016/j.chemphyslip.2013.12.008. This article has 62 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.chemphyslip.2013.12.008)